April 27, 2020 / 11:56 AM / a month ago

BRIEF-Six Covid-19 Patients Treated With Redhill’S Opaganib Under Compassionate Use Show Objective Clinical Improvement

April 27 (Reuters) -

* SIX COVID-19 PATIENTS TREATED WITH REDHILL’S OPAGANIB UNDER COMPASSIONATE USE SHOW OBJECTIVE CLINICAL IMPROVEMENT

* REDHILL BIOPHARMA - FIVE OF SIX PATIENTS HAVE BEEN WEANED FROM OXYGEN ALTOGETHER, SIXTH PATIENT CONTINUES TO IMPROVE

* REDHILL BIOPHARMA - OPAGANIB HAS BEEN WELL TOLERATED AND NO PATIENT REQUIRED MECHANICAL VENTILATION FOLLOWING TREATMENT WITH OPAGANIB

* REDHILL BIOPHARMA LTD - TO DATE, TWO PATIENTS HAVE SAFELY COMPLETED 14 DAYS OF OPAGANIB THERAPY, WHICH HAS BEEN WELL TOLERATED Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below